Spdr S&P Biotech Etf (XBI) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Spdr S&P Biotech Etf (XBI)

156.20

-0.62 (0.40%)

as of Sep 11, 2026, 8:00:00 pm Market Open.

24 watching

Investor Insights

Sep 13, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

The Spdr S&P Biotech ETF (XBI-N) has garnered mixed reviews from experts, reflecting varied perspectives on its current performance and potential. While some analysts express concerns about its recent underperformance and volatility compared to the healthcare sector, others highlight a significant resurgence in the biotech field since summer 2023, suggesting that it could present a strong investment opportunity. The ETF's equal weight methodology allows for broad exposure to early and mid-stage biotech companies, which may mitigate volatility while capturing explosive growth potential. Furthermore, ongoing advancements in AI for drug discovery may provide additional upside, making XBI an attractive option for investors looking to diversify beyond large technology stocks. Despite current market fluctuations, there are bullish forecasts for XBI, with some experts predicting short-term unwinding could be a chance to buy into this promising sector.

Consensus

Positive

Valuation

Fair Value

Similar

IBB

SELL ON STRENGTH

Exposure to the covid vaccine is quite minimal in this ETF. Very short term over-bought and he expects a 10-15% correction. Trim some exposure into strength. Longer term, the biotech sector looks good.

BUY

The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

PAST TOP PICK

(A Top Pick October 10/17 Up 0.2%) He stepped out of this a month after they recommended it. It broke down on the relative strength measure and has not done much else since. He likes the healthcare space still however.

TOP PICK

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

COMMENT

He likes biotech. This ETF will be an equal weight of all the names, so you are going to get some of the smaller cap names, which will have benefited you. Thinks there is lots of growth left in this space.

BUY

Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.

Showing 16 to 21 of 21 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Capital Wealth Planning

Greg Newman

Scotia Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Spdr S&P Biotech Etf (XBI)